BHST
BioHarvest Sciences Inc. Common StockBHST
BHST
About: BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Employees: 87
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
47% more capital invested
Capital invested by funds: $545K [Q4 2024] → $803K (+$257K) [Q1 2025]
33% more funds holding
Funds holding: 6 [Q4 2024] → 8 (+2) [Q1 2025]
0.23% more ownership
Funds ownership: 0.51% [Q4 2024] → 0.74% (+0.23%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$14
94%
upside
Avg. target
$14
94%
upside
High target
$14
94%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Amit Dayal | 94%upside $14 | Buy Reiterated | 8 Apr 2025 |
Financial journalist opinion
Based on 9 articles about BHST published over the past 30 days
Positive
Proactive Investors
1 week ago
BioHarvest Sciences launches Informed Sport-certified daily chew - ICYMI
BioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel talked with Proactive about the company's newest addition to its Vinia product line, a daily “2X formula” chew, specifically designed for athletes and highly active consumers. The chew delivers 12mg of Piceid Resveratrol, doubling the dose found in the original capsule format.
Positive
Proactive Investors
1 week ago
BioHarvest Sciences launches Informed Sport-certified VINIA DailyChews 2X Formula
BioHarvest Sciences Inc. (NASDAQ:BHST) has launched a new product tailored to athletes and individuals with active lifestyles called VINIA DailyChews 2X Formula. The developer of botanical-based wellness products using its proprietary Botanical Synthesis said this new product is now available for purchase in a 30-count pack through VINIA.com.
Neutral
Newsfile Corp
1 week ago
BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles
Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com.
Positive
Zacks Investment Research
1 week ago
What Makes BioHarvest Sciences Inc. (BHST) a Good Fit for 'Trend Investing'
BioHarvest Sciences Inc. (BHST) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Positive
Proactive Investors
3 weeks ago
BioHarvest enters fragrance industry with AI edge - ICYMI
BioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week announced a new contract targeting the plant-based fragrance compound market, using its proprietary botanical synthesis platform. CEO Ilan Sobel said the contract focuses on a rare plant under threat from overharvesting and habitat loss.
Positive
Proactive Investors
3 weeks ago
BioHarvest inks fragrance compound deal in move into multi-billion-dollar scents market
BioHarvest Sciences Inc. (NASDAQ:BHST) said it has signed a contract to develop a plant-based fragrance compound using its patented Botanical Synthesis technology, marking the company's entry into the multi-billion-dollar fragrance and scents industry. The contract, with an undisclosed commercial partner, targets the development of a compound derived from a threatened plant species facing overharvesting and habitat loss.
Neutral
Newsfile Corp
3 weeks ago
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.
Positive
Proactive Investors
4 weeks ago
BioHarvest Sciences advances CDMO deal with major pharmaceutical company - ICYMI
BioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel joined Proactive to discuss the company's transition to stage two of its partnership with a pharmaceutical company. This marks a key milestone in the development of plant-derived biological materials for use in approved drugs.
Neutral
Seeking Alpha
4 weeks ago
BioHarvest Sciences Inc. (BHST) Q1 2025 Earnings Call Transcript
BioHarvest Sciences Inc. (NASDAQ:BHST ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Amit Dayal - H.C. Wainwright Susan Anderson - Canaccord Genuity Nicholas Sherwood - Maxim Group Hunter Diamond - Diamond Equity Research Operator Greetings, and welcome to the BioHarvest Sciences First Quarter 2025 Corporate Update Conference Call.
Negative
Zacks Investment Research
4 weeks ago
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
Charts implemented using Lightweight Charts™